{"filing":{"accession_number":"0001104659-26-080930","cik":"0001346830","ticker":"TVRD","company_name":"Tvardi Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-07","report_date":null,"primary_document":"tm2619879d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1346830/000110465926080930/tm2619879d1_8k.htm"},"events":[{"id":16307,"run_id":14557,"accession_number":"0001104659-26-080930","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Tvardi disclosed Phase 1 clinical trial results for TTI-109, a next-generation STAT3 inhibitor, confirming prodrug design, improved tolerability versus the parent compound TTI-101, and pharmacodynamic evidence of target engagement. The company announced plans to advance TTI-109 into dermatologic and GI diseases pending IND clearance and additional funding. This is a material clinical development milestone for a clinical-stage biopharmaceutical company, but does not fit the specific categories of earnings release, M\u0026A, litigation, or other named event types—it is a material operational/strategic update on product development progress.","company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","filing_date":"2026-07-07","form":"8-K","submitted_at":null,"items":[{"id":14367,"accession_number":"0001104659-26-080930","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Tvardi disclosed Phase 1 clinical trial results for TTI-109, a next-generation STAT3 inhibitor, confirming prodrug design, improved tolerability versus the parent compound TTI-101, and pharmacodynamic evidence of target engagement. The company announced plans to advance TTI-109 into dermatologic and GI diseases pending IND clearance and additional funding. This is a material clinical development milestone for a clinical-stage biopharmaceutical company, but does not fit the specific categories of earnings release, M\u0026A, litigation, or other named event types—it is a material operational/strategic update on product development progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:10:05.648885+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14367,"accession_number":"0001104659-26-080930","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Tvardi disclosed Phase 1 clinical trial results for TTI-109, a next-generation STAT3 inhibitor, confirming prodrug design, improved tolerability versus the parent compound TTI-101, and pharmacodynamic evidence of target engagement. The company announced plans to advance TTI-109 into dermatologic and GI diseases pending IND clearance and additional funding. This is a material clinical development milestone for a clinical-stage biopharmaceutical company, but does not fit the specific categories of earnings release, M\u0026A, litigation, or other named event types—it is a material operational/strategic update on product development progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:10:05.648885+00:00","company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","filing_date":"2026-07-07"}]}